Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation

Go back to Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
Amgen Inc (NASDAQ: AMGN) Delayed: 443.84 +4.51 (1.03%)
Previous Close $439.33    52 Week High $176.85 
Open $440.31    52 Week Low $133.64 
Day High $445.87    P/E 66.84 
Day Low $435.51    EPS $6.64 
Volume 2,462,186